Stock Research for ABSCF

ABSCF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABSCF Stock Chart & Research Data

The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABSCF Due diligence Resources & Stock Charts

The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABSCF Detailed Price Forecast - CNN Money CNN View ABSCF Detailed Summary - Google Finance
Yahoo View ABSCF Detailed Summary - Yahoo! Finance Zacks View ABSCF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABSCF Trends & Analysis - Trade-Ideas Barrons View ABSCF Major Holders - Barrons
NASDAQ View ABSCF Call Transcripts - NASDAQ Seeking View ABSCF Breaking News & Analysis - Seeking Alpha
Spotlight View ABSCF Annual Report - CompanySpotlight.com OTC Report View ABSCF OTC Short Report - OTCShortReport.com
TradeKing View ABSCF Fundamentals - TradeKing Charts View ABSCF SEC Filings - Bar Chart
WSJ View Historical Prices for ABSCF - The WSJ Morningstar View Performance/Total Return for ABSCF - Morningstar
MarketWatch View the Analyst Estimates for ABSCF - MarketWatch CNBC View the Earnings History for ABSCF - CNBC
StockMarketWatch View the ABSCF Earnings - StockMarketWatch MacroAxis View ABSCF Buy or Sell Recommendations - MacroAxis
Bullish View the ABSCF Bullish Patterns - American Bulls Short Pains View ABSCF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABSCF Stock Mentions - StockTwits PennyStocks View ABSCF Stock Mentions - PennyStockTweets
Twitter View ABSCF Stock Mentions - Twitter Invest Hub View ABSCF Investment Forum News - Investor Hub
Yahoo View ABSCF Stock Mentions - Yahoo! Message Board Seeking Alpha View ABSCF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABSCF - SECform4.com Insider Cow View Insider Transactions for ABSCF - Insider Cow
CNBC View ABSCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABSCF - OTC Markets
Yahoo View Insider Transactions for ABSCF - Yahoo! Finance NASDAQ View Institutional Holdings for ABSCF - NASDAQ


Stock Charts

FinViz View ABSCF Stock Insight & Charts - FinViz.com StockCharts View ABSCF Investment Charts - StockCharts.com
BarChart View ABSCF Stock Overview & Charts - BarChart Trading View View ABSCF User Generated Charts - Trading View




Latest Financial News for ABSCF


What Are The Drivers Of AB Science SA’s (EPA:AB) Risks?
Posted on Friday September 14, 2018

Anyone researching AB Science SA (EPA:AB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...


AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
Posted on Monday July 23, 2018

FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC) to continue, based on the planned trend-analysis, the study AB12010 in the third and fourth-line treatment of metastatic colorectal cancer. Study AB12010 is an open-label, randomized, adaptive phase 2/3 study comparing the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus Best Supportive Care in third or fourth line of treatment of patients with metastatic colorectal cancer.


AB Science situation and future prospects presented during the Combined General Shareholders' Meeting held on July 29 2018
Posted on Tuesday July 03, 2018

A Combined General Shareholders` Meeting was held on July 29, 2018 in Paris. The shareholders present or represented together held 18,861,180 shares, representing respectively 45.39% of the total number of shares and 60.75% of the voting rights. All resolutions submitted to the vote of the shareholders have been adopted, with the exception of the 24th resolution, which was rejected.


AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in prostate cancer
Posted on Tuesday June 19, 2018

FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC), following the interim analysis of study AB12003 in the first-line treatment of metastatic castrate resistant prostate cancer (mCRPC). Study AB12003 is an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study in first-line metastatic castrate resistant prostate cancer (mCRPC).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.